BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review.
Acalabrutinib
Acute respiratory distress syndrome
Bruton's tyrosine kinase
COVID-19
Cytokine storm
Hospitalization
Ibrutinib
SARS-CoV-2
X-linked agammaglobulinemia
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
18
04
2021
revised:
30
07
2021
accepted:
31
07
2021
pubmed:
6
8
2021
medline:
6
8
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive. To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19. We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded. 125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs. BTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration.
Identifiants
pubmed: 34352390
pii: S1521-6616(21)00153-4
doi: 10.1016/j.clim.2021.108816
pmc: PMC8327577
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108816Commentaires et corrections
Type : UpdateOf
Informations de copyright
Published by Elsevier Inc.
Références
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Medicine (Baltimore). 1996 Nov;75(6):287-99
pubmed: 8982147
Trials. 2020 Jul 31;21(1):691
pubmed: 32736596
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Leuk Res. 2009 Oct;33(10):1319-27
pubmed: 19395025
Clin Immunol. 2021 May;226:108716
pubmed: 33774179
mBio. 2020 Aug 7;11(4):
pubmed: 32769090
Tanaffos. 2020 Nov;19(2):85-88
pubmed: 33262793
Cureus. 2020 Nov 25;12(11):e11701
pubmed: 33391934
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Blood. 2015 Nov 5;126(19):2213-9
pubmed: 26337493
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
J Immunol. 2006 Mar 15;176(6):3635-41
pubmed: 16517732
Clin Immunol. 2020 Sep;218:108516
pubmed: 32574709
Cancer Cell. 2017 Jun 12;31(6):833-843.e5
pubmed: 28552327
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569
pubmed: 32319118
Clin Immunol. 2021 Feb;223:108652
pubmed: 33333256
Chest. 2013 Jul;144(1):258-265
pubmed: 23258406
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Eur J Haematol. 2018 Apr;100(4):325-334
pubmed: 29285806
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Front Immunol. 2020 Aug 28;11:2158
pubmed: 32983178
Mol Cancer Res. 2021 Apr;19(4):549-554
pubmed: 33328281
Cancer J. 2019 Nov/Dec;25(6):386-393
pubmed: 31764119
Pediatr Rheumatol Online J. 2017 Jan 17;15(1):5
pubmed: 28095869
Sci Immunol. 2021 May 13;6(59):
pubmed: 34446527
Sci Immunol. 2021 Apr 7;6(58):
pubmed: 33827897
Br J Haematol. 2020 Jul;190(2):e73-e76
pubmed: 32433778
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
Blood. 2011 Jan 27;117(4):1329-39
pubmed: 21063022
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5791-6
pubmed: 22454496
Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2
pubmed: 32707096
Leuk Res. 2019 Dec;87:106233
pubmed: 31639635
Clin Immunol. 2008 Feb;126(2):148-54
pubmed: 18271077
Leukemia. 2020 Sep;34(9):2354-2363
pubmed: 32647324
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Tohoku J Exp Med. 2020;250(4):271-278
pubmed: 32321874
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Blood. 2016 Oct 13;128(15):1940-1943
pubmed: 27503501
Front Immunol. 2017 Nov 08;8:1454
pubmed: 29167667
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L52-L58
pubmed: 29516781
Clin Immunol. 2020 Jun;215:108410
pubmed: 32276140
Blood. 2020 Sep 3;136(10):1115-1116
pubmed: 32882019
Nature. 2021 Feb;590(7847):635-641
pubmed: 33429418
Blood. 2011 Jul 28;118(4):936-45
pubmed: 21659545
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
Mol Med. 2019 Jan 15;25(1):3
pubmed: 30646846
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
J Clin Invest. 2020 Apr 1;130(4):1793-1807
pubmed: 31895698
Blood. 2013 Oct 10;122(15):2539-49
pubmed: 23886836
Lancet Respir Med. 2021 Feb;9(2):196-206
pubmed: 33189161
Clin Immunol. 2020 Dec;221:108603
pubmed: 33022386
Int Immunopharmacol. 2021 Jan;90:107123
pubmed: 33168411
N Engl J Med. 2020 Nov 5;383(19):1886-1887
pubmed: 32459913